Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Penumbra's annualizedGross Profit for the quarter that ended in Dec. 2023 was $748 Mil.
Penumbra's average Total Assets over the quarter that ended in Dec. 2023 was $1,512 Mil. Therefore, Penumbra's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 49.46%.
Penumbra Gross-Profit-to-Asset % Historical Data
The historical data trend for Penumbra's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Penumbra's Gross-Profit-to-Asset %
For the Medical Devices subindustry, Penumbra's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Penumbra's Gross-Profit-to-Asset % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Penumbra's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where Penumbra's Gross-Profit-to-Asset % falls into.
Penumbra Gross-Profit-to-Asset % Calculation
Penumbra's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Dec. 2023) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
Penumbra Gross-Profit-to-Asset % Related Terms
Thank you for viewing the detailed overview of Penumbra's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are primarily sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PEN has been successfully added to your 